#4 - Johnson & Johnson (NYSE:JNJ)
No list of pharmaceutical stocks would seem complete without Johnson & Johnson (NYSE: JNJ) on the list. Like Pfizer, JNJ was one of the big winners in the Covid-19 vaccine race. And one of the recent news items driving the stock is the company’s application to provide booster shots for its vaccine. A decision is expected later in October.
This could be the catalyst that JNJ stock needs to break it out of the doldrums. So far, the stock is flat in 2021. However, JNJ stock is trading in the middle of its 52-week range and analysts give the stock a 20% upside from its current level.
Of course, Johnson & Johnson also has a number of its products currently in the market. And investors shouldn’t forget that Johnson & Johnson is part of the elite Dividend Kings club. The company has increased its dividend every year for the last 59 years. And currently, it sports a dividend yield of 2.67%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More - Current Price
- $156.30
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $175.94 (12.6% Upside)
